[go: up one dir, main page]

ATE427758T1 - Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen - Google Patents

Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen

Info

Publication number
ATE427758T1
ATE427758T1 AT03735232T AT03735232T ATE427758T1 AT E427758 T1 ATE427758 T1 AT E427758T1 AT 03735232 T AT03735232 T AT 03735232T AT 03735232 T AT03735232 T AT 03735232T AT E427758 T1 ATE427758 T1 AT E427758T1
Authority
AT
Austria
Prior art keywords
reactions
inhibitor
inflammable
inhibit
chemotactic factor
Prior art date
Application number
AT03735232T
Other languages
English (en)
Inventor
Philippe Tessier
Carle Ryckman
Karen Vandal
Pascal Rouleau
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Application granted granted Critical
Publication of ATE427758T1 publication Critical patent/ATE427758T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03735232T 2002-07-05 2003-06-20 Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen ATE427758T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39352002P 2002-07-05 2002-07-05

Publications (1)

Publication Number Publication Date
ATE427758T1 true ATE427758T1 (de) 2009-04-15

Family

ID=30115596

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03735232T ATE427758T1 (de) 2002-07-05 2003-06-20 Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen

Country Status (7)

Country Link
US (4) US7553488B2 (de)
EP (1) EP1519749B1 (de)
AT (1) ATE427758T1 (de)
AU (1) AU2003236762A1 (de)
CA (1) CA2489860C (de)
DE (1) DE60327075D1 (de)
WO (1) WO2004004770A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE411038T1 (de) * 2003-03-28 2008-10-15 Univ Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
US20070231317A1 (en) * 2004-07-13 2007-10-04 Universite Laval S100 Protein Inhibitors for Treating Leukemia
WO2006122723A1 (en) * 2005-05-19 2006-11-23 Vaecgene Biotech Gmbh Method for the prevention and/or treatment of autoimmune disease or allogeneic transplant rejections
WO2009133940A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
RU2571230C2 (ru) 2008-04-30 2015-12-20 Дженомикс Ко., Лтд. Способ сбора функциональных клеток in vivo с высокой эффективностью
US8283131B2 (en) * 2008-10-28 2012-10-09 Assistance Publique-Hopitaux De Paris Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock
RU2016135937A (ru) 2009-10-28 2018-12-11 Дженомикс Ко., Лтд. Средства для стимуляции регенерации тканей путем привлечения мезинхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь
WO2012056044A1 (en) 2010-10-30 2012-05-03 Imperial Innovations Ltd Treatment for dupuytren's disease
WO2012147470A1 (ja) 2011-04-26 2012-11-01 株式会社ジェノミックス 組織再生を誘導するためのペプチドとその利用
WO2012155049A1 (en) * 2011-05-11 2012-11-15 Medimmune, Llc Treatment of lung inflammation
PL2913059T3 (pl) 2012-10-25 2018-09-28 Genomix Co., Ltd. Nowy sposób leczenia urazu rdzenia kręgowego z zastosowaniem fragmentu HMGB1
PL2913058T3 (pl) 2012-10-25 2018-04-30 Genomix Co., Ltd. Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1
US10005833B2 (en) * 2015-01-02 2018-06-26 Washington State University Methods of treating inflammation associated airway diseases and viral infections
EA201990253A1 (ru) * 2015-07-13 2019-06-28 Юниверсите Лаваль Гуманизированные антитела против s100a9 и их применение
US10894082B2 (en) 2015-09-14 2021-01-19 UNIVERSITé LAVAL Anti-S100A8 for treating leukemia
AU2017248273B2 (en) 2016-04-08 2024-03-14 180 Therapeutics Lp Method of treating early stage Dupuytren's disease
CN110494154B (zh) 2017-01-27 2023-09-29 斯特姆里姆有限公司 心肌病、陈旧性心肌梗塞及慢性心力衰竭的治疗剂
CN110446929A (zh) * 2017-02-07 2019-11-12 优生学有限公司 用于诊断由无菌性松动引起的植入物修复的植入物相关风险的生物标记物
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
WO2020051460A1 (en) * 2018-09-07 2020-03-12 Sanford Burnham Prebys Medical Discovery Institute Methods of diagnosis and treatment of inflammatory bowel disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3789413T2 (de) 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
EP0550506B1 (de) * 1990-09-05 2002-11-20 The Heart Research Institute Limited Chemotaktische faktoren
US5248825A (en) * 1990-09-20 1993-09-28 Merrell Dow Pharmaceuticals Inc. Calcium uptake inhibitors
ATE359515T1 (de) * 1997-02-12 2007-05-15 Electrophoretics Ltd Proteinmarker für lungenkrebs und deren verwendung
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
EP1118681A1 (de) * 1998-09-29 2001-07-25 Asahi Kasei Kabushiki Kaisha Verfahren zur kontrollierten freisetzung von granulaten
WO2003057715A2 (en) * 2001-12-28 2003-07-17 The Regents Of The University Of California Novel ligand involved in the transmigration of leukocytes .
ATE411038T1 (de) 2003-03-28 2008-10-15 Univ Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
US20070231317A1 (en) 2004-07-13 2007-10-04 Universite Laval S100 Protein Inhibitors for Treating Leukemia

Also Published As

Publication number Publication date
CA2489860C (en) 2015-02-10
US20050288211A1 (en) 2005-12-29
US20130273075A1 (en) 2013-10-17
US8282925B2 (en) 2012-10-09
US20140348849A1 (en) 2014-11-27
WO2004004770A1 (en) 2004-01-15
AU2003236762A1 (en) 2004-01-23
EP1519749B1 (de) 2009-04-08
US20090275516A1 (en) 2009-11-05
DE60327075D1 (de) 2009-05-20
CA2489860A1 (en) 2004-01-15
EP1519749A1 (de) 2005-04-06
US7553488B2 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
ATE427758T1 (de) Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen
EA200802285A1 (ru) Бивалентные миметики smac и их применения
BRPI0407195A (pt) inibidor de histona desacetilase, composição, e, método para inibir histona desacetilase em uma célula
WO2012178208A3 (en) Selective inhibitors of histone deacetylase isoform 6 and methods thereof
BRPI1013388A2 (pt) composição de limpeza que compreende uma alfa-amilase e uma protease e método de limpeza de um tecido ou superficie dura
EP3354640A3 (de) Mif-hemmer und verwendungen davon
GB2441727A (en) Corrosion inhibitor for acids
MX2009011069A (es) Mimeticos de smac diazo biciclicos y usos de los mismos.
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
WO2010065850A3 (en) Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA200801784A1 (ru) Ингибиторы е1 активирующих ферментов
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
WO2005069888A3 (en) Smac peptidomimetics and the uses thereof
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
DE602004019542D1 (de) Proteasome inhibitoren und deren verwendung
MX2024009001A (es) Inhibidores de la pcsk9 y metodos de uso de los mismos.
MX375059B (es) Compuestos para el tratamiento de cancer.
EA201001860A1 (ru) Ингибиторы дпп-4 для лечения неалкогольной жировой дистрофии печени
EA200702128A1 (ru) Фенильные и пиридильные модуляторы lta4h
NO20081636L (no) FAP - inhibitorer
EP2666472A3 (de) Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
RU2017117194A (ru) Лечение рака иммуностимуляторами

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties